Stocktoria
Adicet Bio, Inc. ACET
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-01-26
Adicet Bio, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $99.1M | $99.3M | $106.0M | $71.2M | $48.9M |
| Operating income | -$122.1M | -$127.6M | -$152.0M | -$72.6M | -$61.4M |
| Interest expense | $36,000 | $4,000 | $25,000 | $80,000 | $176,000 |
| Income tax | $0 | $0 | $0 | $0 | -$125,000 |
| Net income | -$116.8M | -$117.1M | -$142.7M | -$69.8M | -$62.0M |
| EPS (diluted) | $-16.95 | $-21.33 | $-3.31 | $-1.70 | $-2.00 |
| Operating cash flow | -$95.2M | -$92.4M | -$93.7M | -$44.8M | -$51.1M |
| Free cash flow | -$97.0M | -$93.5M | -$98.2M | -$61.5M | -$64.1M |
| Cash & equivalents | $38.9M | $56.5M | $159.7M | $257.7M | $277.5M |
| Total assets | $192.4M | $220.2M | $207.3M | $330.7M | $338.9M |
| Total liabilities | $33.1M | $33.6M | $37.1M | $38.4M | $35.8M |
| Shareholders' equity | $159.2M | $186.6M | $170.2M | $292.3M | $303.1M |
Source: SEC EDGAR filings · CIK 0001720580 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.